Compare YRD & INKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | YRD | INKT |
|---|---|---|
| Founded | 2012 | 2017 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 62.5M | 53.7M |
| IPO Year | 2015 | 2021 |
| Metric | YRD | INKT |
|---|---|---|
| Price | $0.36 | $9.82 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $42.50 |
| AVG Volume (30 Days) | ★ 2.4M | 9.6K |
| Earning Date | 11-24-2026 | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $425.24 | N/A |
| Revenue Next Year | N/A | $44.74 |
| P/E Ratio | $1.86 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.36 | $8.48 |
| 52 Week High | $5.60 | $15.27 |
| Indicator | YRD | INKT |
|---|---|---|
| Relative Strength Index (RSI) | 26.97 | 49.37 |
| Support Level | $0.36 | $9.05 |
| Resistance Level | $1.05 | $12.27 |
| Average True Range (ATR) | 0.05 | 0.82 |
| MACD | -0.02 | 0.06 |
| Stochastic Oscillator | 1.10 | 61.25 |
Yiren Digital Ltd is an AI-powered platform providing a comprehensive suite of financial and lifestyle services in China. Its mission is to elevate customers' financial well-being and enhance their quality of life by delivering digital financial services, tailor-made insurance solutions, and premium lifestyle services. The company supports clients at various growth stages, addressing financing needs arising from consumption and production activities, while aiming to augment the overall well-being and security of individuals, families, and businesses.
MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the discovery, development and manufacturing of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. iNKT cells offer distinct therapeutic advantages as a platform for allogeneic therapy in that the cells naturally home to tissues, aid clearance of tumors and infected cells, and suppress graft-versus-host-disease. Its product candidate, agenT-797, is an off-the-shelf, allogeneic, native iNKT cell therapy. It operates its business in single segment.